For Recombinants To Approach mRNA Speed, US FDA Urged To Select Monovalent COVID Boosters

US FDA and BARDA ask makers of recombinant protein SARS-CoV-2 vaccines how they could match mRNA vaccines in post-strain-selection turnaround time for annual booster doses. The reply: give them a fighting chance by selecting just one strain instead of two.